ACT 541468

Drug Profile

ACT 541468

Alternative Names: ACT 541468

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Insomnia

Most Recent Events

  • 26 Apr 2017 Actelion completes a phase I trial in healthy volunteers in Netherlands (NCT03101189)
  • 15 Mar 2017 Actelion initiates a phase I trial in healthy volunteers in Netherlands (NCT03101189)
  • 01 Feb 2017 Actelion completes a phase I pharmacokinetics trial in Healthy volunteers in Germany (PO, Capsule) (NCT03017495)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top